First biologic to be approved for children aged six to 11 years with condition
News
UK secures another two million doses of Moderna’s COVID-19 vaccine
New agreement takes supply up to seven million doses in total
Symkevi/Kalydeco cleared for use in young CF patients
The combination is the first available to treat the underlying cause of CF in this patient group.
EU to review Merck’s targeted lung cancer drug
Tepotinib could be the first treatment on the market for NSCLC in adults harbouring METex14 skipping alterations
NICE turns down Novartis’ Adakveo
Trial results and cost-effectiveness are too uncertain for NHS use, the Institute said
NHS to trial innovative cancer blood test
It is hoped that the test will help detect cancer at a much earlier stage
NICE backs use of new treatment for multiple myeloma
Sanofi’s Sarclisa gets the final green light for use by the NHS with funding from the CDF
Moderna signs deal with EU for 160 million COVID-19 vaccine doses
Delivery of vaccine doses to EU could begin by early 2021
Janssen’s Tremfya approved for active psoriatic arthritis
Tremfya is a first-in-class treatment for the disease, shown to improve disease measures and quality of life
Mixed reaction to chancellor’s spending review
Chancellor Rishi Sunak hands out extra £3 billion to NHS and £14.6 billion in funding for R&D
BMS inks drug discovery deal with Schrödinger
Deal will focus on developing small molecules against a number of diseases
COVID-19 pandemic has emphasised existing health inequalities, research finds
New report conducted by Imperial College London researchers and Philips UK highlights issues within the NHS
Over half of pharmacists report that COVID-19 has impacted their mental health
Survey from The Royal Pharmacy Society shows impact of pandemic on pharmacists’ mental health
GSK launches late-stage study of RSV vaccine in pregnant mothers
Shot will be evaluated in pregnant mothers and their newborn infants
Amgen hands back heart failure programme rights to Cytokinetics
Omecamtiv mecarbil and AMG 594 rights transitioned back to biotech
